Dr. Greene is a seasoned pharmaceutical research professional with success both in large pharmaceutical companies and in CROs. He has a PhD and post-doctoral training in psychology and neuroscience, with a focus on the neuroanatomical and neurochemical bases of learning and memory. His career has spanned the full range of clinical development from preclinical pharmacology through late-stage clinical development, successful NDA and MAA submissions, and post approval commitments and label extensions. Dr. Greene has published numerous manuscripts and over thirty abstracts, all focused in CNS research from the bench to clinical work.
With over 25 years of experience in the pharmaceutical industry, first as a Lilly Fellow at the Universitè Louis Pasteur in Strasbourg, France, Paul has obtained roles of progressing responsibility at major pharmaceutical companies and CROs. He has experience across a range of CNS disease states with very deep concentrations in mood disorders and schizophrenia. He has worked extensively in pediatric and elderly populations including special institutional environments. At GlaxoSmithKline Dr. Greene led the clinical team through the creation and execution of a clinical development plan for a major marketed product for bipolar disorder. He also led the submission team for a successful NDA and MAA for that product and wrote the Integrated Summary of Efficacy and the Integrated Summary of Benefits and Risks.
Having led global project management teams, a rater training enterprise, and large customer relationships at Syneos Health, Dr. Greene brings scientific, operational, and partnership expertise to the relationships in his remit. Paul is Senior Vice President, Global Client Solutions at Syneos Health.